1 Study Coverage
    1.1 Cancer Immunotherapies Product Introduction
    1.2 Market by Type
        1.2.1 Global Cancer Immunotherapies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Monoclonal Antibodies (MABs)
        1.2.3 Cancer Vaccines
        1.2.4 Immunomodulators
        1.2.5 Adoptive Cell transfer
        1.2.6 Checkpoint Inhibitors
    1.3 Market by Application
        1.3.1 Global Cancer Immunotherapies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Breast Cancer
        1.3.3 Leukemia
        1.3.4 Lymphoma
        1.3.5 Melanoma
        1.3.6 Colorectal Cancer
        1.3.7 Non-Small Cell Lung Cancer
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Cancer Immunotherapies Sales Estimates and Forecasts 2017-2028
    2.2 Global Cancer Immunotherapies Revenue Estimates and Forecasts 2017-2028
    2.3 Global Cancer Immunotherapies Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Cancer Immunotherapies Sales by Region
        2.4.1 Global Cancer Immunotherapies Sales by Region (2017-2022)
        2.4.2 Global Sales Cancer Immunotherapies by Region (2023-2028)
    2.5 Global Cancer Immunotherapies Revenue by Region
        2.5.1 Global Cancer Immunotherapies Revenue by Region (2017-2022)
        2.5.2 Global Cancer Immunotherapies Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Cancer Immunotherapies Sales by Manufacturers
        3.1.1 Global Top Cancer Immunotherapies Manufacturers by Sales (2017-2022)
        3.1.2 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Immunotherapies in 2021
    3.2 Global Cancer Immunotherapies Revenue by Manufacturers
        3.2.1 Global Cancer Immunotherapies Revenue by Manufacturers (2017-2022)
        3.2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2021
    3.3 Global Cancer Immunotherapies Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Cancer Immunotherapies Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Cancer Immunotherapies Sales by Type
        4.1.1 Global Cancer Immunotherapies Historical Sales by Type (2017-2022)
        4.1.2 Global Cancer Immunotherapies Forecasted Sales by Type (2023-2028)
        4.1.3 Global Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    4.2 Global Cancer Immunotherapies Revenue by Type
        4.2.1 Global Cancer Immunotherapies Historical Revenue by Type (2017-2022)
        4.2.2 Global Cancer Immunotherapies Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    4.3 Global Cancer Immunotherapies Price by Type
        4.3.1 Global Cancer Immunotherapies Price by Type (2017-2022)
        4.3.2 Global Cancer Immunotherapies Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Cancer Immunotherapies Sales by Application
        5.1.1 Global Cancer Immunotherapies Historical Sales by Application (2017-2022)
        5.1.2 Global Cancer Immunotherapies Forecasted Sales by Application (2023-2028)
        5.1.3 Global Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    5.2 Global Cancer Immunotherapies Revenue by Application
        5.2.1 Global Cancer Immunotherapies Historical Revenue by Application (2017-2022)
        5.2.2 Global Cancer Immunotherapies Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    5.3 Global Cancer Immunotherapies Price by Application
        5.3.1 Global Cancer Immunotherapies Price by Application (2017-2022)
        5.3.2 Global Cancer Immunotherapies Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Cancer Immunotherapies Market Size by Type
        6.1.1 North America Cancer Immunotherapies Sales by Type (2017-2028)
        6.1.2 North America Cancer Immunotherapies Revenue by Type (2017-2028)
    6.2 North America Cancer Immunotherapies Market Size by Application
        6.2.1 North America Cancer Immunotherapies Sales by Application (2017-2028)
        6.2.2 North America Cancer Immunotherapies Revenue by Application (2017-2028)
    6.3 North America Cancer Immunotherapies Market Size by Country
        6.3.1 North America Cancer Immunotherapies Sales by Country (2017-2028)
        6.3.2 North America Cancer Immunotherapies Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Cancer Immunotherapies Market Size by Type
        7.1.1 Europe Cancer Immunotherapies Sales by Type (2017-2028)
        7.1.2 Europe Cancer Immunotherapies Revenue by Type (2017-2028)
    7.2 Europe Cancer Immunotherapies Market Size by Application
        7.2.1 Europe Cancer Immunotherapies Sales by Application (2017-2028)
        7.2.2 Europe Cancer Immunotherapies Revenue by Application (2017-2028)
    7.3 Europe Cancer Immunotherapies Market Size by Country
        7.3.1 Europe Cancer Immunotherapies Sales by Country (2017-2028)
        7.3.2 Europe Cancer Immunotherapies Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Cancer Immunotherapies Market Size by Type
        8.1.1 Asia Pacific Cancer Immunotherapies Sales by Type (2017-2028)
        8.1.2 Asia Pacific Cancer Immunotherapies Revenue by Type (2017-2028)
    8.2 Asia Pacific Cancer Immunotherapies Market Size by Application
        8.2.1 Asia Pacific Cancer Immunotherapies Sales by Application (2017-2028)
        8.2.2 Asia Pacific Cancer Immunotherapies Revenue by Application (2017-2028)
    8.3 Asia Pacific Cancer Immunotherapies Market Size by Region
        8.3.1 Asia Pacific Cancer Immunotherapies Sales by Region (2017-2028)
        8.3.2 Asia Pacific Cancer Immunotherapies Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Cancer Immunotherapies Market Size by Type
        9.1.1 Latin America Cancer Immunotherapies Sales by Type (2017-2028)
        9.1.2 Latin America Cancer Immunotherapies Revenue by Type (2017-2028)
    9.2 Latin America Cancer Immunotherapies Market Size by Application
        9.2.1 Latin America Cancer Immunotherapies Sales by Application (2017-2028)
        9.2.2 Latin America Cancer Immunotherapies Revenue by Application (2017-2028)
    9.3 Latin America Cancer Immunotherapies Market Size by Country
        9.3.1 Latin America Cancer Immunotherapies Sales by Country (2017-2028)
        9.3.2 Latin America Cancer Immunotherapies Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Cancer Immunotherapies Market Size by Type
        10.1.1 Middle East and Africa Cancer Immunotherapies Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Cancer Immunotherapies Revenue by Type (2017-2028)
    10.2 Middle East and Africa Cancer Immunotherapies Market Size by Application
        10.2.1 Middle East and Africa Cancer Immunotherapies Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Cancer Immunotherapies Revenue by Application (2017-2028)
    10.3 Middle East and Africa Cancer Immunotherapies Market Size by Country
        10.3.1 Middle East and Africa Cancer Immunotherapies Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Cancer Immunotherapies Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Amgen
        11.1.1 Amgen Corporation Information
        11.1.2 Amgen Overview
        11.1.3 Amgen Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Amgen Recent Developments
    11.2 AstraZeneca
        11.2.1 AstraZeneca Corporation Information
        11.2.2 AstraZeneca Overview
        11.2.3 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 AstraZeneca Recent Developments
    11.3 Roche
        11.3.1 Roche Corporation Information
        11.3.2 Roche Overview
        11.3.3 Roche Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Roche Recent Developments
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Corporation Information
        11.4.2 Bristol-Myers Squibb Overview
        11.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Bristol-Myers Squibb Recent Developments
    11.5 Bayer
        11.5.1 Bayer Corporation Information
        11.5.2 Bayer Overview
        11.5.3 Bayer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Bayer Recent Developments
    11.6 Merck
        11.6.1 Merck Corporation Information
        11.6.2 Merck Overview
        11.6.3 Merck Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Merck Recent Developments
    11.7 ARMO BioSciences (Eli Lilly)
        11.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
        11.7.2 ARMO BioSciences (Eli Lilly) Overview
        11.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 ARMO BioSciences (Eli Lilly) Recent Developments
    11.8 Novartis
        11.8.1 Novartis Corporation Information
        11.8.2 Novartis Overview
        11.8.3 Novartis Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Novartis Recent Developments
    11.9 Pfizer
        11.9.1 Pfizer Corporation Information
        11.9.2 Pfizer Overview
        11.9.3 Pfizer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Pfizer Recent Developments
    11.10 Johnson & Johnson
        11.10.1 Johnson & Johnson Corporation Information
        11.10.2 Johnson & Johnson Overview
        11.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Johnson & Johnson Recent Developments
    11.11 AbbVie
        11.11.1 AbbVie Corporation Information
        11.11.2 AbbVie Overview
        11.11.3 AbbVie Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 AbbVie Recent Developments
    11.12 Gilead Sciences
        11.12.1 Gilead Sciences Corporation Information
        11.12.2 Gilead Sciences Overview
        11.12.3 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Gilead Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Cancer Immunotherapies Industry Chain Analysis
    12.2 Cancer Immunotherapies Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Cancer Immunotherapies Production Mode & Process
    12.4 Cancer Immunotherapies Sales and Marketing
        12.4.1 Cancer Immunotherapies Sales Channels
        12.4.2 Cancer Immunotherapies Distributors
    12.5 Cancer Immunotherapies Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Cancer Immunotherapies Industry Trends
    13.2 Cancer Immunotherapies Market Drivers
    13.3 Cancer Immunotherapies Market Challenges
    13.4 Cancer Immunotherapies Market Restraints
14 Key Findings in The Global Cancer Immunotherapies Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Cancer Immunotherapies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Monoclonal Antibodies (MABs)
    Table 3. Major Manufacturers of Cancer Vaccines
    Table 4. Major Manufacturers of Immunomodulators
    Table 5. Major Manufacturers of Adoptive Cell transfer
    Table 6. Major Manufacturers of Checkpoint Inhibitors
    Table 7. Global Cancer Immunotherapies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Cancer Immunotherapies Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
    Table 10. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
    Table 11. Global Cancer Immunotherapies Sales by Region (2023-2028) & (K Units)
    Table 12. Global Cancer Immunotherapies Sales Market Share by Region (2023-2028)
    Table 13. Global Cancer Immunotherapies Revenue by Region (2017-2022) & (US$ Million)
    Table 14. Global Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
    Table 15. Global Cancer Immunotherapies Revenue by Region (2023-2028) & (US$ Million)
    Table 16. Global Cancer Immunotherapies Revenue Market Share by Region (2023-2028)
    Table 17. Global Cancer Immunotherapies Sales by Manufacturers (2017-2022) & (K Units)
    Table 18. Global Cancer Immunotherapies Sales Share by Manufacturers (2017-2022)
    Table 19. Global Cancer Immunotherapies Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 20. Global Cancer Immunotherapies Revenue Share by Manufacturers (2017-2022)
    Table 21. Cancer Immunotherapies Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 22. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2021)
    Table 24. Cancer Immunotherapies Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers Cancer Immunotherapies Product Offered
    Table 26. Date of Manufacturers Enter into Cancer Immunotherapies Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 29. Global Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 30. Global Cancer Immunotherapies Sales Share by Type (2017-2022)
    Table 31. Global Cancer Immunotherapies Sales Share by Type (2023-2028)
    Table 32. Global Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 33. Global Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 34. Global Cancer Immunotherapies Revenue Share by Type (2017-2022)
    Table 35. Global Cancer Immunotherapies Revenue Share by Type (2023-2028)
    Table 36. Cancer Immunotherapies Price by Type (2017-2022) & (USD/Unit)
    Table 37. Global Cancer Immunotherapies Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 38. Global Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 39. Global Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 40. Global Cancer Immunotherapies Sales Share by Application (2017-2022)
    Table 41. Global Cancer Immunotherapies Sales Share by Application (2023-2028)
    Table 42. Global Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 43. Global Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 44. Global Cancer Immunotherapies Revenue Share by Application (2017-2022)
    Table 45. Global Cancer Immunotherapies Revenue Share by Application (2023-2028)
    Table 46. Cancer Immunotherapies Price by Application (2017-2022) & (USD/Unit)
    Table 47. Global Cancer Immunotherapies Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 48. North America Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 49. North America Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 50. North America Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 51. North America Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 52. North America Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 53. North America Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 54. North America Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 55. North America Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 56. North America Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
    Table 57. North America Cancer Immunotherapies Sales by Country (2023-2028) & (K Units)
    Table 58. North America Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
    Table 59. North America Cancer Immunotherapies Revenue by Country (2023-2028) & (US$ Million)
    Table 60. Europe Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 61. Europe Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 62. Europe Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 63. Europe Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 64. Europe Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 65. Europe Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 66. Europe Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 67. Europe Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 68. Europe Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
    Table 69. Europe Cancer Immunotherapies Sales by Country (2023-2028) & (K Units)
    Table 70. Europe Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
    Table 71. Europe Cancer Immunotherapies Revenue by Country (2023-2028) & (US$ Million)
    Table 72. Asia Pacific Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 73. Asia Pacific Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 74. Asia Pacific Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 75. Asia Pacific Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 76. Asia Pacific Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 77. Asia Pacific Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 78. Asia Pacific Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 79. Asia Pacific Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 80. Asia Pacific Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
    Table 81. Asia Pacific Cancer Immunotherapies Sales by Region (2023-2028) & (K Units)
    Table 82. Asia Pacific Cancer Immunotherapies Revenue by Region (2017-2022) & (US$ Million)
    Table 83. Asia Pacific Cancer Immunotherapies Revenue by Region (2023-2028) & (US$ Million)
    Table 84. Latin America Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 85. Latin America Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 86. Latin America Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 87. Latin America Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 88. Latin America Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 89. Latin America Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 90. Latin America Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 91. Latin America Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 92. Latin America Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
    Table 93. Latin America Cancer Immunotherapies Sales by Country (2023-2028) & (K Units)
    Table 94. Latin America Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
    Table 95. Latin America Cancer Immunotherapies Revenue by Country (2023-2028) & (US$ Million)
    Table 96. Middle East and Africa Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
    Table 97. Middle East and Africa Cancer Immunotherapies Sales by Type (2023-2028) & (K Units)
    Table 98. Middle East and Africa Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
    Table 99. Middle East and Africa Cancer Immunotherapies Revenue by Type (2023-2028) & (US$ Million)
    Table 100. Middle East and Africa Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
    Table 101. Middle East and Africa Cancer Immunotherapies Sales by Application (2023-2028) & (K Units)
    Table 102. Middle East and Africa Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
    Table 103. Middle East and Africa Cancer Immunotherapies Revenue by Application (2023-2028) & (US$ Million)
    Table 104. Middle East and Africa Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
    Table 105. Middle East and Africa Cancer Immunotherapies Sales by Country (2023-2028) & (K Units)
    Table 106. Middle East and Africa Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
    Table 107. Middle East and Africa Cancer Immunotherapies Revenue by Country (2023-2028) & (US$ Million)
    Table 108. Amgen Corporation Information
    Table 109. Amgen Description and Major Businesses
    Table 110. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 111. Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Amgen Recent Developments
    Table 113. AstraZeneca Corporation Information
    Table 114. AstraZeneca Description and Major Businesses
    Table 115. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 116. AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. AstraZeneca Recent Developments
    Table 118. Roche Corporation Information
    Table 119. Roche Description and Major Businesses
    Table 120. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 121. Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Roche Recent Developments
    Table 123. Bristol-Myers Squibb Corporation Information
    Table 124. Bristol-Myers Squibb Description and Major Businesses
    Table 125. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 126. Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Bristol-Myers Squibb Recent Developments
    Table 128. Bayer Corporation Information
    Table 129. Bayer Description and Major Businesses
    Table 130. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 131. Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Bayer Recent Developments
    Table 133. Merck Corporation Information
    Table 134. Merck Description and Major Businesses
    Table 135. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 136. Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Merck Recent Developments
    Table 138. ARMO BioSciences (Eli Lilly) Corporation Information
    Table 139. ARMO BioSciences (Eli Lilly) Description and Major Businesses
    Table 140. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 141. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. ARMO BioSciences (Eli Lilly) Recent Developments
    Table 143. Novartis Corporation Information
    Table 144. Novartis Description and Major Businesses
    Table 145. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 146. Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Novartis Recent Developments
    Table 148. Pfizer Corporation Information
    Table 149. Pfizer Description and Major Businesses
    Table 150. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 151. Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. Pfizer Recent Developments
    Table 153. Johnson & Johnson Corporation Information
    Table 154. Johnson & Johnson Description and Major Businesses
    Table 155. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 156. Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 157. Johnson & Johnson Recent Developments
    Table 158. AbbVie Corporation Information
    Table 159. AbbVie Description and Major Businesses
    Table 160. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 161. AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 162. AbbVie Recent Developments
    Table 163. Gilead Sciences Corporation Information
    Table 164. Gilead Sciences Description and Major Businesses
    Table 165. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 166. Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 167. Gilead Sciences Recent Developments
    Table 168. Key Raw Materials Lists
    Table 169. Raw Materials Key Suppliers Lists
    Table 170. Cancer Immunotherapies Distributors List
    Table 171. Cancer Immunotherapies Customers List
    Table 172. Cancer Immunotherapies Market Trends
    Table 173. Cancer Immunotherapies Market Drivers
    Table 174. Cancer Immunotherapies Market Challenges
    Table 175. Cancer Immunotherapies Market Restraints
    Table 176. Research Programs/Design for This Report
    Table 177. Key Data Information from Secondary Sources
    Table 178. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cancer Immunotherapies Product Picture
    Figure 3. Global Cancer Immunotherapies Market Share by Type in 2021 & 2028
    Figure 3. Monoclonal Antibodies (MABs) Product Picture
    Figure 4. Cancer Vaccines Product Picture
    Figure 5. Immunomodulators Product Picture
    Figure 6. Adoptive Cell transfer Product Picture
    Figure 7. Checkpoint Inhibitors Product Picture
    Figure 8. Global Cancer Immunotherapies Market Share by Application in 2021 & 2028
    Figure 9. Breast Cancer
    Figure 10. Leukemia
    Figure 11. Lymphoma
    Figure 12. Melanoma
    Figure 13. Colorectal Cancer
    Figure 14. Non-Small Cell Lung Cancer
    Figure 15. Cancer Immunotherapies Report Years Considered
    Figure 16. Global Cancer Immunotherapies Sales 2017-2028 (K Units)
    Figure 17. Global Cancer Immunotherapies Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 18. Global Cancer Immunotherapies Revenue 2017-2028 (US$ Million)
    Figure 19. Global Cancer Immunotherapies Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 20. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
    Figure 21. Global Cancer Immunotherapies Sales Market Share by Region (2023-2028)
    Figure 22. North America Cancer Immunotherapies Sales YoY (2017-2028) & (K Units)
    Figure 23. North America Cancer Immunotherapies Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Cancer Immunotherapies Sales YoY (2017-2028) & (K Units)
    Figure 25. Europe Cancer Immunotherapies Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Asia-Pacific Cancer Immunotherapies Sales YoY (2017-2028) & (K Units)
    Figure 27. Asia-Pacific Cancer Immunotherapies Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Latin America Cancer Immunotherapies Sales YoY (2017-2028) & (K Units)
    Figure 29. Latin America Cancer Immunotherapies Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. Middle East & Africa Cancer Immunotherapies Sales YoY (2017-2028) & (K Units)
    Figure 31. Middle East & Africa Cancer Immunotherapies Revenue YoY (2017-2028) & (US$ Million)
    Figure 32. The Cancer Immunotherapies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 33. The Top 5 and 10 Largest Manufacturers of Cancer Immunotherapies in the World: Market Share by Cancer Immunotherapies Revenue in 2021
    Figure 34. Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 35. Global Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 36. Global Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 37. Global Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 38. Global Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 39. North America Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 40. North America Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 41. North America Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 42. North America Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 43. North America Cancer Immunotherapies Sales Share by Country (2017-2028)
    Figure 44. North America Cancer Immunotherapies Revenue Share by Country (2017-2028)
    Figure 45. U.S. Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 46. Canada Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 47. Europe Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 48. Europe Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 49. Europe Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 50. Europe Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 51. Europe Cancer Immunotherapies Sales Share by Country (2017-2028)
    Figure 52. Europe Cancer Immunotherapies Revenue Share by Country (2017-2028)
    Figure 53. Germany Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 54. France Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 55. U.K. Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 56. Italy Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 57. Russia Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 58. Asia Pacific Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 59. Asia Pacific Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 60. Asia Pacific Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 61. Asia Pacific Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 62. Asia Pacific Cancer Immunotherapies Sales Share by Region (2017-2028)
    Figure 63. Asia Pacific Cancer Immunotherapies Revenue Share by Region (2017-2028)
    Figure 64. China Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 65. Japan Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 66. South Korea Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 67. India Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 68. Australia Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 69. Taiwan Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 70. Indonesia Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 71. Thailand Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 72. Malaysia Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 73. Philippines Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 74. Latin America Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 75. Latin America Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 76. Latin America Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 77. Latin America Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 78. Latin America Cancer Immunotherapies Sales Share by Country (2017-2028)
    Figure 79. Latin America Cancer Immunotherapies Revenue Share by Country (2017-2028)
    Figure 80. Mexico Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 81. Brazil Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 82. Argentina Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 83. Middle East and Africa Cancer Immunotherapies Sales Market Share by Type (2017-2028)
    Figure 84. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Type (2017-2028)
    Figure 85. Middle East and Africa Cancer Immunotherapies Sales Market Share by Application (2017-2028)
    Figure 86. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Application (2017-2028)
    Figure 87. Middle East and Africa Cancer Immunotherapies Sales Share by Country (2017-2028)
    Figure 88. Middle East and Africa Cancer Immunotherapies Revenue Share by Country (2017-2028)
    Figure 89. Turkey Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 90. Saudi Arabia Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 91. U.A.E Cancer Immunotherapies Revenue (2017-2028) & (US$ Million)
    Figure 92. Cancer Immunotherapies Value Chain
    Figure 93. Cancer Immunotherapies Production Process
    Figure 94. Channels of Distribution
    Figure 95. Distributors Profiles
    Figure 96. Bottom-up and Top-down Approaches for This Report
    Figure 97. Data Triangulation
    Figure 98. Key Executives Interviewed